A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Metastatic Breast CancerHormone Receptor Positive
Interventions
DRUG

Palbociclib

Given orally (PO)

DRUG

Tamoxifen

Given orally (PO)

DRUG

Fulvestrant

Given by intramuscular (IM) injection.

Trial Locations (9)

20007

Georgetown University, Washington D.C.

21287

Johns Hopkins University, Baltimore

37240

Vanderbilt University, Nashville

46202

Indiana University, Indianapolis

48109

University of Michigan, Ann Arbor

60637

University of Chicago, Chicago

77030

Baylor College of Medicine, Houston

94143

University of California, San Francisco, San Francisco

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Translational Breast Cancer Research Consortium

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

lead

University of California, San Francisco

OTHER

NCT02384239 - A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter